MX2012012684A - Factor villa viia conjugado para coagulacion de la sangre. - Google Patents
Factor villa viia conjugado para coagulacion de la sangre.Info
- Publication number
- MX2012012684A MX2012012684A MX2012012684A MX2012012684A MX2012012684A MX 2012012684 A MX2012012684 A MX 2012012684A MX 2012012684 A MX2012012684 A MX 2012012684A MX 2012012684 A MX2012012684 A MX 2012012684A MX 2012012684 A MX2012012684 A MX 2012012684A
- Authority
- MX
- Mexico
- Prior art keywords
- blood coagulation
- coagulation factor
- factor viia
- conjugated blood
- fviia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona un polímero biocompatible conjugado a FVIIa por medio de uno o más residuos de cisteína, adecuadamente por medio de un enlazador a través de un enlace disulfuro reducido en FVIIa, y composiciones farmacéuticas que comprenden esas formas conjugadas de FVIIa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1007356.7A GB201007356D0 (en) | 2010-04-30 | 2010-04-30 | Conjugated factor VIIa |
PCT/GB2011/000663 WO2011135308A1 (en) | 2010-04-30 | 2011-04-28 | Conjugated blood coagulation factor viia |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012012684A true MX2012012684A (es) | 2013-04-03 |
Family
ID=42289986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012012684A MX2012012684A (es) | 2010-04-30 | 2011-04-28 | Factor villa viia conjugado para coagulacion de la sangre. |
Country Status (28)
Country | Link |
---|---|
US (1) | US9309507B2 (es) |
EP (1) | EP2563403B1 (es) |
JP (2) | JP2013525415A (es) |
KR (1) | KR20130055620A (es) |
CN (1) | CN102971013B (es) |
AP (1) | AP2012006574A0 (es) |
AU (1) | AU2011247148B2 (es) |
CA (1) | CA2796870A1 (es) |
CL (1) | CL2012003038A1 (es) |
CO (1) | CO6660500A2 (es) |
CR (1) | CR20120580A (es) |
DK (1) | DK2563403T3 (es) |
EA (1) | EA201290941A1 (es) |
EC (1) | ECSP12012315A (es) |
ES (1) | ES2503570T3 (es) |
GB (2) | GB201007356D0 (es) |
HK (1) | HK1175999A1 (es) |
IL (1) | IL222565A (es) |
MX (1) | MX2012012684A (es) |
MY (1) | MY160510A (es) |
NI (1) | NI201200161A (es) |
NZ (1) | NZ603938A (es) |
PE (1) | PE20130253A1 (es) |
PL (1) | PL2563403T3 (es) |
RU (1) | RU2012144554A (es) |
SG (1) | SG184573A1 (es) |
WO (1) | WO2011135308A1 (es) |
ZA (1) | ZA201208988B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0720282B8 (pt) | 2006-12-15 | 2021-05-25 | Baxalta GmbH | construção proteica, composição farmacêutica, e, kit |
RU2533619C2 (ru) | 2009-07-27 | 2014-11-20 | Лайпоксен Текнолоджиз Лимитед | Гликополисиалирование белков, не являющихся белками свертывания крови |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
CA2769326A1 (en) | 2009-07-27 | 2011-02-10 | Baxter International Inc. | Blood coagulation protein conjugates |
PL2459224T3 (pl) | 2009-07-27 | 2017-08-31 | Baxalta GmbH | Koniugaty białka związanego z krzepnięciem krwi |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
CA2822591C (en) | 2010-12-22 | 2020-12-29 | Baxter International Inc. | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
EP2838566A2 (en) * | 2012-04-16 | 2015-02-25 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
WO2014210546A1 (en) | 2013-06-27 | 2014-12-31 | University Of Washington Through Its Center For Commercialization | Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders |
GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
WO1998032466A1 (en) | 1997-01-29 | 1998-07-30 | Polymasc Pharmaceuticals Plc | Pegylation process |
EP2319541A1 (en) | 2000-02-11 | 2011-05-11 | Bayer HealthCare LLC | Factor VII or VIIA-like conjugates |
ES2432967T3 (es) * | 2001-03-22 | 2013-12-05 | Novo Nordisk Health Care Ag | Derivados del Factor VII de coagulación |
US7235638B2 (en) | 2001-03-22 | 2007-06-26 | Novo Nordisk Healthcare A/G | Coagulation factor VII derivatives |
ES2354419T3 (es) | 2002-05-01 | 2011-03-14 | Bayer Schering Pharma Aktiengesellschaft | Nuevas proteínas de fusión de trombomodulina dirigidas hacia el factor tisular como agentes anticoagulantes. |
DE60336555D1 (de) | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
UA86744C2 (en) * | 2002-06-21 | 2009-05-25 | Ново Нордиск Хэлс Кеа Аг | Pegylated factor vii glycoforms |
US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
DE60329627D1 (de) | 2002-12-31 | 2009-11-19 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
ES2911435T3 (es) | 2003-02-26 | 2022-05-19 | Nektar Therapeutics | Conjugados de polímero-resto de Factor VIII |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
US20060198819A1 (en) | 2003-08-08 | 2006-09-07 | Novo Nordisk Healthcare A/G | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
US7579444B2 (en) * | 2004-06-30 | 2009-08-25 | Nektar Therapeutics Al, Corporation | Polymer-factor IX moiety conjugates |
WO2006013202A2 (en) | 2004-08-02 | 2006-02-09 | Novo Nordisk Health Care Ag | Conjugation of fvii |
PH12014500352A1 (en) | 2004-11-12 | 2015-07-20 | Bayer Healthcare Llc | Site-directed modification of fviii |
EP1893230A2 (en) | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
WO2007126808A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc | Pegylated factor viii |
JP5570809B2 (ja) | 2006-09-01 | 2014-08-13 | ノボ ノルディスク ヘルス ケア アーゲー | 修飾タンパク質 |
BRPI0720282B8 (pt) | 2006-12-15 | 2021-05-25 | Baxalta GmbH | construção proteica, composição farmacêutica, e, kit |
WO2008098930A1 (en) | 2007-02-14 | 2008-08-21 | Biocompatibes Uk Limited | Derivatisation of biological molecules |
WO2008127702A2 (en) | 2007-04-13 | 2008-10-23 | Catalyst Biosciences, Inc. | Modified factor vii polypetides and uses thereof |
DK2209494T3 (en) | 2007-10-09 | 2016-10-03 | Polytherics Ltd | New conjugated proteins and peptides |
US20110183906A1 (en) * | 2008-04-24 | 2011-07-28 | Celtic Pharma Peg Ltd. | Factor ix conjugates with extended half-lives |
DK2326349T3 (en) * | 2008-07-21 | 2015-05-26 | Polytherics Ltd | Novel Reagents and Methods for Conjugation of Biological Molecules |
EP2334337A1 (en) | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of opioid growth factor peptides |
EP2334336A1 (en) | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of osteocalcin peptides |
EP2341942A1 (en) | 2008-09-19 | 2011-07-13 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
WO2010045321A2 (en) | 2008-10-15 | 2010-04-22 | Baxter International Inc. | Pegylation of recombinant blood coagulation factors in the presence of bound antibodies |
KR101929641B1 (ko) | 2008-10-17 | 2018-12-14 | 박스알타 인코퍼레이티드 | 낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자 |
KR20110093775A (ko) | 2008-11-03 | 2011-08-18 | 바이엘 헬스케어 엘엘씨 | 혈우병 치료 방법 |
GB0823309D0 (en) | 2008-12-19 | 2009-01-28 | Univ Bath | Functionalising reagents and their uses |
CA2748662A1 (en) | 2009-01-19 | 2010-07-22 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase-cleavable bioprotective moiety |
GB0912485D0 (en) | 2009-07-17 | 2009-08-26 | Polytherics Ltd | Improved conjugation method |
US20130040888A1 (en) | 2010-02-16 | 2013-02-14 | Novo Nordisk A/S | Factor VIII Molecules With Reduced VWF Binding |
CN105664175B (zh) | 2010-02-21 | 2019-07-23 | 拜耳医药保健有限公司 | 用于活化和缀合生物分子的方法 |
-
2010
- 2010-04-30 GB GBGB1007356.7A patent/GB201007356D0/en not_active Ceased
-
2011
- 2011-04-28 CA CA2796870A patent/CA2796870A1/en active Pending
- 2011-04-28 US US13/643,504 patent/US9309507B2/en not_active Expired - Fee Related
- 2011-04-28 MY MYPI2012004682A patent/MY160510A/en unknown
- 2011-04-28 PE PE2012002103A patent/PE20130253A1/es not_active Application Discontinuation
- 2011-04-28 KR KR1020127031387A patent/KR20130055620A/ko not_active Application Discontinuation
- 2011-04-28 EA EA201290941A patent/EA201290941A1/ru unknown
- 2011-04-28 ES ES11719041.3T patent/ES2503570T3/es active Active
- 2011-04-28 NZ NZ603938A patent/NZ603938A/xx not_active IP Right Cessation
- 2011-04-28 MX MX2012012684A patent/MX2012012684A/es not_active Application Discontinuation
- 2011-04-28 SG SG2012076790A patent/SG184573A1/en unknown
- 2011-04-28 AU AU2011247148A patent/AU2011247148B2/en not_active Ceased
- 2011-04-28 WO PCT/GB2011/000663 patent/WO2011135308A1/en active Application Filing
- 2011-04-28 GB GB1220669.4A patent/GB2492738B/en not_active Expired - Fee Related
- 2011-04-28 DK DK11719041.3T patent/DK2563403T3/da active
- 2011-04-28 RU RU2012144554/15A patent/RU2012144554A/ru not_active Application Discontinuation
- 2011-04-28 CN CN201180021895.1A patent/CN102971013B/zh not_active Expired - Fee Related
- 2011-04-28 JP JP2013506736A patent/JP2013525415A/ja active Pending
- 2011-04-28 EP EP11719041.3A patent/EP2563403B1/en active Active
- 2011-04-28 PL PL11719041T patent/PL2563403T3/pl unknown
- 2011-04-28 AP AP2012006574A patent/AP2012006574A0/xx unknown
-
2012
- 2012-10-21 IL IL222565A patent/IL222565A/en not_active IP Right Cessation
- 2012-10-29 CL CL2012003038A patent/CL2012003038A1/es unknown
- 2012-10-29 NI NI201200161A patent/NI201200161A/es unknown
- 2012-11-14 CR CR20120580A patent/CR20120580A/es unknown
- 2012-11-15 CO CO12207049A patent/CO6660500A2/es unknown
- 2012-11-28 EC ECSP12012315 patent/ECSP12012315A/es unknown
- 2012-11-28 ZA ZA2012/08988A patent/ZA201208988B/en unknown
-
2013
- 2013-03-15 HK HK13103240.7A patent/HK1175999A1/xx not_active IP Right Cessation
-
2015
- 2015-02-05 JP JP2015021550A patent/JP2015110636A/ja not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2492738A (en) | Conjugated blood coagulation factor VIIA | |
GB2492935A (en) | Conjugated blood coagulation factor VIII | |
CY1118661T1 (el) | Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων | |
CY1116264T1 (el) | Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2 | |
MX339201B (es) | Compuestos de sulfonamida y métodos para elaborarlos y usarlos. | |
MY156951A (en) | Micromirs | |
MX2013007236A (es) | Composiciones fluidas que comprenden un agente de estructuracion. | |
CY1111454T1 (el) | Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων | |
DE602007010764D1 (en) | Benzamidglucokinaseaktivatoren | |
MY161595A (en) | Oral care compositions | |
UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
TN2011000471A1 (en) | Pharmaceutical composition presenting anti-inflammatory properties | |
MX343035B (es) | Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina. | |
WO2011005510A3 (en) | Peptide conjugates and uses thereof | |
MX2016004702A (es) | Polipeptidos del factor vii de coagulacion. | |
CY1115266T1 (el) | Φαρμακευτικες συνθεσεις αερολυματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης | |
DE602006020155D1 (de) | Pharmazeutische wundheilungs-zusammensetzungen in ren und natriumhyaluronat | |
MX2011009277A (es) | Composicion de leucocito activada. | |
UA92604C2 (ru) | Композиция стансопорфина с физиологической осмотической концентрацией и ее применение | |
WO2009132234A3 (en) | Medical devices, polymers, compositions, and methods for delivering a haloacetate | |
EA200801678A1 (ru) | Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом | |
MY157826A (en) | Fluid compositions comprising a structuring agent | |
UA102529C2 (en) | Microribonucleic acids | |
GB201013343D0 (en) | Compositions and methods for inducing platelet aggregation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
HH | Correction or change in general | ||
FA | Abandonment or withdrawal |